Vetter participates in eight drug launches in 2023

Broad portfolio for early and late clinical phases actively supports product development for injectable drugs

Vetter Development Service

The pharmaceutical service provider Vetter Pharma has successfully completed eight market launches of complex medicinal products in 2023. The products were accompanied and supported during their development phases by the comprehensive services of the Vetter Development Service. The drugs, which are now on the market worldwide, are used in oncology and for the treatment of autoimmune and cardiovascular diseases, among others. Their properties and applications are very diverse and range from emergency medication to life-improving long-term therapies. The method of application is also varied and ranges from self-treatment at home to administration by medical professionals.

“Bringing a promising therapy through the clinical phase to market readiness and launch is a challenging journey that culminates years of development work. Our holistic development service offerings build on one another and become interlinked,” shared Dr. Claus Feussner, Senior Vice President Vetter Development Service. “This allows us to support our customer’s products throughout the entire development cycle to commercialization and beyond. Our individualized capabilities have allowed us to support more than 50 market launches over the past five years.”

Vetter is currently involved in over 200 projects in early and late clinical phases

Vetter has significantly expanded its clinical service portfolio in recent years, both in terms of production and personnel capacities as well as analytical services. The Vetter Development Service is one of the manufacturer's three pillars and complements commercial aseptic manufacturing as well as the assembly and packaging of injection systems. The pharmaceutical service provider currently supports more than 200 projects in early and late clinical phases as well as during the product life cycle. With two specialised production sites in Skokie, Illinois, in the US, and in Rankweil, Vorarlberg, in Austria, Vetter supports the manufacture of clinical trial samples in phases I and II. The late clinical development phase with process design, method transfer and handover to quality and production for commercial production and market launch takes place in Ravensburg.